KLRK1 and melanoma: However, even though the effects of BRAFi/MEKi combination on melanoma cell immunogenicity has been previously studied (Pieper et al., 2018; Frazao et al., 2020; Harbers et al., 2021), little is known about the impact of single MEKi or combined BRAFi/MEKi on the NKG2D system on drug sensitive cells.